目的 探討利腦心片聯(lián)合替格瑞洛治療不穩(wěn)定心絞痛的臨床療效。方法 選取2021年3月—2023年2月在北京市大興區(qū)人民醫(yī)院治療的不穩(wěn)定心絞痛患者96例，采用隨機數(shù)字表法將患者分為對照組（48例）和治療組（48例）。對照組患者口服替格瑞洛片，首次負荷劑量180 mg，之后劑量改為90 mg/次，2次/d。治療組患者在對照組基礎(chǔ)上口服利腦心片，3片/次，3次/d。兩組患者治療6個月。觀察兩組患者臨床療效，比較治療前后兩組患者血小板反應(yīng)指數(shù)（PRI）、腺苷二磷酸誘導(dǎo)的血小板-纖維蛋白凝塊強度（MAADP）及血清C反應(yīng)蛋白（CRP）、單核細胞趨化蛋白-1（MCP-1）和基質(zhì)金屬蛋白酶-9（MMP-9）水平。結(jié)果 治療后，治療組總有效率為93.75%，明顯高于對照組79.17%（P＜0.05）。治療后，兩組PRI、MAADP、CRP、MCP-1、MMP-9水平均低于治療前（P＜0.05），且治療組明顯低于對照組（P＜0.05）。結(jié)論 利腦心片聯(lián)合替格瑞洛治療不穩(wěn)定心絞痛安全有效，可有效降低血栓形成風(fēng)險，且不增加出血風(fēng)險，改善體內(nèi)炎癥反應(yīng)。

Objective To explore the clinical efficacy of Linaoxin Tablets combined with ticagrelor in treatment of unstable angina pectoris. Methods A total of 96 patients with unstable angina pectoris treated in Daxing District People's Hospital of Beijing from March 2021 to February 2023 were selected and divided into control group (48 cases) and treatment group (48 cases) by random number table method. Patients in the control group were po administered with Ticagrelor Tablets, the initial loading dose was 180 mg, and then the dose was changed to 90 mg/time, twice daily. Patients in the treatment group were po administered with Linaoxin Tablets on the basis of the control group, 3 tablets/time, three times daily. Patients in two groups were treated for 6 months. After treatment, the clinical evaluations were evaluated, the levels of PRI, MAADP, CRP, MCP-1, and MMP-9 in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 93.75%, which was significantly higher than that of the control group (79.17%, P < 0.05). After treatment, the levels of PRI, MAADP, CRP, MCP-1, and MMP-9 in two groups were lower than those before treatment (P < 0.05), and these indexes levels in the treatment group were significantly lower than the control group (P < 0.05). Conclusion Linaoxin Tablets combined with ticagrelor is safe and effective in treatment of unstable angina pectoris, can effectively reduce the risk of thrombosis without increasing the risk of bleeding and improve the inflammatory response in the body.

R972

首都衛(wèi)生發(fā)展科研專項項目（2020-4-7082）